Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Apr 10;4(4):CD002201.
doi: 10.1002/14651858.CD002201.pub6.

Omega-3 fatty acid supplementation for cystic fibrosis

Helen Watson  1 , Caroline Stackhouse  2
Affiliations
Meta-Analysis

Omega-3 fatty acid supplementation for cystic fibrosis

Helen Watson et al. Cochrane Database Syst Rev. .

Abstract

Background: Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review.

Objectives: To determine whether there is evidence that omega-3 polyunsaturated fatty acid supplementation reduces morbidity and mortality and to identify any adverse events associated with supplementation.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of last search: 01 April 2020. We also searched online study registries and contacted authors. Date of last search: 12 February 2020.

Selection criteria: Randomised controlled trials in people with cystic fibrosis comparing omega-3 fatty acid supplements with placebo.

Data collection and analysis: Two authors independently selected studies for inclusion, extracted data and assessed the risk of bias of the studies. The quality of the evidence was assessed using GRADE.

Main results: The searches identified 23 studies; five studies with 106 participants (children and adults) were included; duration of studies and interventions differed. Two studies compared omega-3 fatty acids to olive oil for six weeks; one study compared omega-3 fatty acids and omega-6 fatty acids to control capsules (customised fatty acid blends) for three months; one study compared a liquid dietary supplement containing omega-3 fatty acids to one without for six months; and one study compared omega-3 fatty acids to a placebo for 12 months. Three studies had a low risk of bias for randomisation, but the risk was unclear in the remaining two studies; all studies had an unclear risk of bias for allocation concealment. Three of the studies adequately blinded participants; the risk of bias for selective reporting was high in one study and unclear for four studies. Two studies reported the number of respiratory exacerbations. At three months, one study (43 participants) reported no change in antibiotic usage. At 12 months the second study (15 participants) reported a reduction in the number of pulmonary exacerbations and cumulative antibiotic days in the supplement group compared to the previous year (no data for the control group); very low-quality evidence means we are unsure whether supplementation has any effect on this outcome. With regards to adverse events, one six-week study (12 participants) reported no difference in diarrhoea between omega-3 or placebo capsules; the very low-quality evidence means we are unsure if supplementation has any effect on this outcome. Additionally, one study reported an increase in steatorrhoea requiring participants to increase their daily dose of pancreatic enzymes, but three studies had already increased pancreatic enzyme dose at study begin so as to reduce the incidence of steatorrhoea. One study (43 participants) reported stomach pains at three months (treatment or control group not specified). One six-week study (19 participants) reported three asthma exacerbations leading to exclusion of participants since corticosteroid treatment could affect affect essential fatty acid metabolism. Four studies reported lung function. One six-week study (19 participants) reported an increase in forced expiratory volume in one second (FEV1) (L) and forced vital capacity (FVC) (L), but the very low-quality evidence means we are unsure if supplementation has any effect on lung function. The remaining studies did not report any difference in lung function at three months (unit of measurement not specified) or at six months and one year (FEV1 % predicted and FVC % predicted). No deaths were reported in any of the five studies. Four studies reported clinical variables. One study reported an increase in Schwachman score and weight alongside a reduction in sputum volume with supplementation compared to placebo at three months (data not analysable). However, three studies reported no differences in either weight at six weeks, in body mass index (BMI) standard deviation (SD) score at six months (very low-quality evidence) or BMI Z score at 12 months. Three studies reported biochemical markers of fatty acid status. One study showed an increase from baseline in both EPA and DHA content of serum phospholipids in the omega-3 group compared to placebo at three months and also a significant decrease in n-6/n-3 ratio in the supplement group compared to placebo; since the quality of the evidence is very low we are not certain that these changes are due to supplementation. One six-month cross-over study showed a higher EPA content of the neutrophil membrane in the supplement group compared to the placebo group, but, no difference in DHA membrane concentration. Furthermore, the leukotriene B4 to leukotriene B5 ratio was lower at six months in the omega-3 group compared to placebo. A one-year study reported a greater increase in the essential fatty acid profile and a decrease in AA levels in the treatment arm compared to placebo.

Authors' conclusions: This review found that regular omega-3 supplements may provide some limited benefits for people with cystic fibrosis with relatively few adverse effects: however, the quality of the evidence across all outcomes was very low. The current evidence is insufficient to draw firm conclusions or recommend routine use of these supplements in people with cystic fibrosis. A large, long-term, multicentre, randomised controlled study is needed to determine any significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the need for additional pancreatic enzymes when providing omega-3 supplementation or olive oil placebo capsules. More research is required to determine the exact dose of pancreatic enzyme required.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Figures

1
1
Study flow (PRISMA) diagram
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Adverse events.
1.2
1.2. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 FEV1 % predicted (post‐treatment).
1.3
1.3. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 FVC % predicted (post treatment).
1.4
1.4. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 BMI (SD score) (post treatment).
1.5
1.5. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 5 EPA and DHA % content of neutrophil membrane (post treatment).
1.6
1.6. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 6 Leukotriene B4 to leukotriene B5 ratio (post treatment).
1.7
1.7. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 7 EPA and DHA content of serum phospholipids (change from baseline).
1.8
1.8. Analysis
Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 8 N6/N3 ratio content of serum phospholipids (change from baseline).
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Hanssens 2016 {published and unpublished data}
    1. Hanssens L, Thiebault I, Lefevre N, Malfroot A, Gaspar V, Knoop C, et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304]
    1. Hanssens L, Thiebaut I, Lefevre N, Malfroot A, Knoop C, Duchateau J, et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] - DOI - PubMed
Henderson 1994 {published data only}
    1. Henderson WR. Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology 1992;14(S8):S21.2. [CFGD Register: GN45a]
    1. Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Becker JU, Ramsey B. Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology 1992;14(S8):311. [CFGD Register: GN45b] - PubMed
    1. Henderson WR Jr, Astley SJ, McCready MT, Kushmerick P, Casey S, Becker JW, et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics 1994;124(3):400‐8. [CFGD Register: GN45c] - PubMed
Keen 2010 {published data only}
    1. Keen C, Olin A, Eriksson S, Ekman A, Lindblad A, Basu S, et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2010;50(5):537‐44. [CFGD Register: GN129b] - PubMed
    1. Keen C, Olin A, Eriksson S, Lindblad A, Ekman A, Basu S, et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a]
Lawrence 1993 {published data only}
    1. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993;342(8869):465‐9. [CFGD Register: GN44a] - PubMed
    1. Lawrence R, Sorrell T. Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine 1993;23:442. [CFGD Register: GN44b]
Panchaud 2006 {published data only}
    1. Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Boulat O, et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition 2006;25(3):418‐27. [CFGD Register: GN109b] - PubMed
    1. Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Roule M. Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis 2005;4 Supplement 1:S88. [CFGD Register: GN109a]

References to studies excluded from this review

Alicandro 2013 {published data only (unpublished sought but not used)}
    1. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzu G, Biffi A, et al. A randomized placebo‐controlled study on high‐dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 2013;88(2):163‐9. [CFGD Register: GN118d; ] - PubMed
    1. Alicandro G, Gagliardini R, Rise P, Santini B, Biffi A, Tirelli S, et al. Oral DHA supplementation in children with CF: a randomized placebo‐controlled study. Pediatric Pulmonology 2011;46 Suppl 34:394. [Abstract no.: 499; CFGD Register: GN118c; ]
    1. Alicandro G, Gagliardini R, Santini B, Rise P, Biffi A, Tirelli AS, et al. Oral DHA supplementation in children with cystic fibrosis: a randomized placebo‐controlled study. Journal of Cystic Fibrosis 2011;10 Suppl 1:S74. [Abstract no.: 290; CFGD Register: GN118b; ] - PubMed
    1. Colombo C, Dacco V, Santini B, Garliardini R, Loi S, Casartelli M, et al. DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial. Pediatric Pulmonology 2008;43 Suppl 31:427. [CFGD Register: GN118a]
Christophe 1992 {published data only}
    1. Christophe A, Robberecht E, Franckx H. Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis. 11th International Cystic Fibrosis Congress, Dublin, Ireland. 1992:MP76. [CFGD Register: GN54]
EUCTR2006‐004155038‐BE {published data only}
    1. EUCTR2006‐004155‐38‐BE. Biochemical effects of a long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis ‐ omega 3 study. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006‐004155‐38‐BE (first received 23 September 2008).
Katz 1996 {published data only}
    1. Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega‐3 fatty acids in patients with cystic fibrosis. Nutrition 1996;12(5):334‐9. [CFGD Register: GN66a] - PubMed
    1. Manner T, Guida L, Katz DP, Askanazi J, Schlotzer E, Wiesse S. Parenteral fish oil administration in patients with cystic fibrosis. Clinical Nutrition 1992;11(11):40. [CFGD Register: GN66c]
    1. Manner T, Katz DP, Askanazi J, Schlotzer E, Furst P. Parenteral fish oil administration in patients with cystic fibrosis. 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition). 1993:440. [CFGD Register: GN66b]
Koletzko 2000 {published data only}
    1. Koletzko B, Tuxen‐Mengedoht M, Muller I, Demmelmair H, Stern M, Steffan J. Polyunsaturated fatty acids improve outcome of cystic fibrosis patients. 13th International Cystic Fibrosis Conference; 2000 June 4‐8; Stockholm. 2000:78. [CFGD Register: GN65b]
    1. Tuxen‐Mengedoht M, Koletzko B, Demmelmair H, Knapp V, Stern M. Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial. Clinical Nutrition 1999;18(Suppl 1):54. [CFGD Register: GN65a]
    1. Tuxen‐Mengedoht M, Koletzko B, Muller I, Demmelmair H, Knapp V, Stern M, et al. Fish‐oil therapy in mucoviscidosis: A randomised double‐blind study [Fischol‐Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde 1999;147(Suppl 2):107. [CFGD Register: GN65c]
Kurlandsky 1994 {published data only}
    1. Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ. The absorption and effect of dietary supplementation with omega‐3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatric Pulmonology 1994;18(4):211‐7. [CFGD Register: GN46] - PubMed
Lloyd‐Still 2006 {published data only}
    1. Lloyd‐Still J, Powers C, Hoffman D, Arterburn L, Benisek D, Lester L. Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis. Pediatric Research 2001;49(4 Suppl):455a. [CFGD Register: GN92d]
    1. Lloyd‐Still J, Powers C, Hoffman D, Boyd‐Trull K, Lester L, Benisek D, et al. A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients. Pediatric Pulmonology 2004;38(Suppl 27):331. [CFGD Register: GN92c] - PubMed
    1. Lloyd‐Still J, Powers C, Hoffman D, Boyd‐Trull K, Lester L, Benisek D, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study. Nutrition 2006;22(1):36‐46. [CFGD Register: GN92e] - PubMed
    1. Lloyd‐Still J, Powers C, Hoffman D, Boyd‐trull K, Arterburn L, Benisek D, et al. Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis. Pediatric Pulmonology 2001;32(Suppl 22):263. [CFGD Register: GN92b]
    1. Powers CA, Lloyd‐Still J, Hoffman D, Arteburn L, Benisek D, Lester L. Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF. Abstracts of the 24th European Cystic Fibrosis Conference. 2001:P133. [CFGD Register: GN92a]
NCT02518672 {published data only}
    1. NCT02518672. Pro‐resolving effect of MAG‐DHA in cystic fibrosis (PREMDIC). clinicaltrials.gov/ct2/show/NCT02518672 (first received 10 August 2015).
NCT02646995 {published data only}
    1. NCT02646995. Lipid formulation to increase the bioavailabilty of fatty acids in cystic fibrosis (CF) patients. clinicaltrials.gov/ct2/show/NCT02646995 (first received 6 January 2016).
NCT02690857 {published data only}
    1. NCT02690857. Study of docosahexanoic acid in patients with cystic fibrosis (CF) (OMEGAMUCO). clinicaltrials.gov/ct2/show/NCT02690857 (first received 24 Feb 2016).
NCT03045198 {published data only}
    1. NCT03045198. Effect of azithromycin on fatty acids in CF. clinicaltrials.gov/ct2/show/NCT03045198 (first received 07 February 2017).
O'Connor 2016 {published data only}
    1. O'Connor MG, Thomsen K, Brown RF, Laposata M, Seegmiller A. Elevated prostaglandin e metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2016;113:46‐9. [CFGD Register: GN250b] - PMC - PubMed
    1. O'connor MG, Thomsen K, Brown RF, Laposata M, Seegmiller AC. DHA supplementation in pediatric CF patients: a randomized, double‐blind clinical trial.. Pediatric Pulmonology. 2015; Vol. Suppl 34:401. [Abstract no.: 582; CFGD Register: GN250a]
O'Sullivan 2011 {published data only}
    1. O'Sullivan B, Baker D, Borowitz D, Comeau A, Cleveland R, Freedman S. The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF. Pediatric Pulmonology 2011;46 Suppl 34:401. [Abstract no.: 519; CFGD Register: GN229; ]
Pastor 2019 {published data only}
    1. Pastor O, Guzman‐Lafuente P, Serna J, Munoz‐Hernandez M, Lopez Neyra A, Garcia‐Rozas P, et al. A comprehensive evaluation of omega‐3 fatty acid supplementation in cystic fibrosis patients using lipidomics. Journal of Nutritional Biochemistry 2019;63:197‐205. [CFGD Register: GN277; DOI: 10.1016/j.jnutbio.2018.09.026] - DOI - PubMed
Romano 1997 {published data only}
    1. Romano L, Gandino M, Fiore P, Shepherd D, Casciaro R, Coccia C, et al. Study on feasibility and results of midterm dietary supplementation in omega‐3 fatty acids. 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167. [CFGD Register: GN67]
Starling 1988 {published data only}
    1. Starling MB, Elliot RB. EPA and cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress. 1988:74. [CFGD Register: GN59]
van Biervliet 2008 {published data only}
    1. Biervliet S, Devos M, Delhaye J, Biervliet J, Robberecht E, Christophe A. Oral DHA supplementation in F508 homozygous cystic fibrosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 2008;78(2):109‐15. [CFGD Register: GN116] - PubMed
Vericel 2019 {published data only}
    1. Vericel E, Mazur S, Colas R, Delaup V, Calzada C, Reix P, et al. Moderate intake of docosahexaenoic acid raises plasma and platelet vitamin E. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2016;115:41‐7. [CFGD Register: GN264; DOI: 10.1016/j.plefa.2016.10.008] - DOI - PubMed

Additional references

Benabdeslam 1998
    1. Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. American Journal of Human Nutrition 1998;67(5):912‐8. - PubMed
CF Trust 2006
    1. Littlewood J, Green M, Stannard W. Finding Out. CF Trust Factsheet 2006.
CF Trust 2015
    1. UK CF Trust. CF Trust Factsheet. Steroid treatment in cystic fibrosis. www.cysticfibrosis.org.uk/˜/media/documents/life‐with‐cf/publications/fa... (accessed 10 January 2020).
CF Trust 2016
    1. UK CF Trust. CF Trust Consensus Documents: Nutritional Management of Cystic Fibrosis. September 2016. www.cysticfibrosis.org.uk/˜/media/documents/the‐work‐we‐do/care/consensu... (accessed 10 January 2020).
Cheng 1999
    1. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD000407] - DOI - PubMed
Corcoran 1937
    1. Corcoran AC, Rabinowitch IM. A study of the blood lipids and blood proteins in Canadian Eastern Arctic Eskimos. Biochemistry Journal 1937;31:343‐8. - PMC - PubMed
Corey 1998
    1. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology 1998;41(6):583‐91. - PubMed
Dodge 1988
    1. Dodge JA. Nutritional requirement in cystic fibrosis: a review. Journal of Pediatric Gastroenterology Nutrition 1988;7(Suppl 1):S8‐11. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Freedman 1999
    1. Freedman SD, Alvarez JG. Pathogenesis of pancreatic disease in cystic fibrosis. Pediatric Pulmonology 1999;Suppl 19:129.
Gaskin 1982
    1. Gaskin K, Gurwitz D, Durie P, Corey M, Levison H, Forstner G. Improved respiratory prognosis in patients with normal fat absorption. Journal of Pediatrics 1982;100(6):857‐62. - PubMed
Gaszo 1989
    1. Gazso A, Kaliman J, Horrobin DF, Sinzinger H. Effects of omega‐3 fatty acids on the prostaglandin system in healthy probands. Wiener Klinische Wochenschrift 1989;101(8):283‐8. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hunt 1985
    1. Hunt B, Geddes DM. Newly diagnosed cystic fibrosis in middle and later life. Thorax 1985;40(1):23‐6. - PMC - PubMed
Imrie 1975
    1. Imrie J, Fagan D, Sturgess J. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and controlled subjects. American Journal Pathology 1975;95(3):697‐708. - PMC - PubMed
Jüni 2001
    1. Jüni P, Douglas G, Altman G, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Konstan 1996
    1. Konstan MW. Treatment of airway inflammation in cystic fibrosis. Current Opinion in Pulmonary Medicine 1996;2(6):452‐6. - PubMed
Lands 2007
    1. Lands LC, Stanojevic S. Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001505.pub2] - DOI - PubMed
Lloyd‐Still 1996
    1. Lloyd‐Still JD, Bibus DM, Powers CA, Johnson SB, Holman RT. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatrica 1996;85(12):1426‐32. - PubMed
Osterud 1995
    1. Osterud B, Elvevoll E, Barstad H, Brox J, Halvorsen H, Lia K, et al. Effect of marine oils supplementation on coagulation and cellular activation in whole blood. Lipids 1995;30(12):1111‐8. - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shwachman 1958
    1. Shwachman H, Kulczycki LL. Long term study of 105 patients with cystic fibrosis. American Journal of Diseases of Children 1958;96(1):6‐10. - PubMed
UK CF Registry 2018
    1. UK CF Trust. UK Cystic Fibrosis Registry Annual Data Report 2018. www.cysticfibrosis.org.uk 2019.
Wilmott 2000
    1. Wilmott RW, Khurana‐Hershui G, Stark JM. Current concepts on pulmonary host defence mechanisms in children. Current Opinion in Pediatrics 2000;12(3):187‐93. - PubMed

References to other published versions of this review

Beckles‐Willson 2002
    1. Beckles‐Willson NNR, Elliott T, Everard MML. Omega‐3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD002201.pub2] - DOI - PubMed
Oliver 2010
    1. Oliver C, Everard M, N'Diaye T. Omega‐3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD002201.pub2] - DOI - PubMed
Oliver 2011
    1. Oliver C, Jahnke N. Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD002201.pub3] - DOI - PubMed
Oliver 2013
    1. Oliver C, Watson H. Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD002201.pub4] - DOI - PubMed
Oliver 2016
    1. Oliver C, Watson H. Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2016, Issue 1. [DOI: 10.1002/14651858.CD002201.pub5] - DOI - PMC - PubMed

Publication types